SUMA Acquisition Corp. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2026; filed November 10, 2026. SUMA is a blank-check company formed to pursue a business combination. It reported no operations or operating revenue and had no definitive agreement with a target as of quarter-end. Its stated search focus is North American technology businesses.
Financial position and results
- Third-quarter results: Net income was $1.40 million, comprising $1.59 million of trust-account interest income less $193,000 of general and administrative costs. Basic and diluted income per share was $0.06.
- Nine-month results: Net income was $2.88 million, including $3.44 million of trust-account interest income and $562,000 of general and administrative costs. Basic and diluted income per share was $0.15.
- Revenue and margins: No operating revenue was generated; operating losses were $193,000 for the quarter and $562,000 for the nine months. Operating margins are not meaningful for this pre-combination SPAC.
- Cash flow: Net cash used in operating activities was $467,000 for the nine months. Financing activities provided $173.8 million, primarily from the IPO and private placement; $172.5 million was invested in the trust account.
- Liquidity: At September 30, cash outside the trust was $848,000, working capital was $622,000, and trust assets were $175.9 million, or $10.20 per redeemable public share. Management said available funds should cover working-capital needs for one year, but warned actual search and transaction costs could exceed estimates.
- Liabilities and equity: Total liabilities were $7.24 million, including a $6.9 million deferred underwriting fee payable only if a business combination closes, and a $45,000 related-party IPO note due on demand. No working-capital loans or long-term debt were outstanding. Shareholders’ deficit was $6.25 million, while 17.25 million public shares were classified as temporary equity subject to redemption.
Changes and outlook
- The IPO closed March 12, 2026, raising $172.5 million from 17.25 million public units; the underwriters fully exercised the over-allotment option. A concurrent private placement raised $4.46 million.
- Because the company began its IPO and trust investment in 2026, the filing provides no prior-year comparable operating-period results. The balance sheet compares September 30, 2026 with December 31, 2025, when the company had no trust assets.
- The company must complete a business combination by March 12, 2028, subject to any permitted earlier or shareholder-approved later date. If it does not, public shares are to be redeemed and the company liquidated, subject to applicable law.
- Management expects increased public-company, diligence, and transaction costs. No specific transaction guidance or target-related outlook was provided.
Risks, contingencies, and other notable matters
- There is no assurance SUMA will identify or complete a suitable transaction. Redemptions, additional financing needs, market conditions, regulation, interest rates, tariffs, supply-chain disruption, and geopolitical events could affect its ability to complete one.
- The $6.9 million deferred underwriting fee reduces proceeds available if a transaction closes. Trust assets may also be exposed to creditor claims; sponsor indemnification may not be collectible because the company has not verified sponsor resources.
- Public rights expire worthless if no business combination is completed; rights convert into one-fifth of a Class A share each upon a qualifying transaction, subject to the filing’s terms.
- The company reported effective disclosure controls as of September 30, 2026, no material litigation known to management, and no material changes to previously disclosed risk factors. No material subsequent events were identified.
Important facts for investors to verify
- Whether SUMA has identified a target or entered a definitive agreement since September 30, and the status of its search before the March 12, 2028 deadline.
- Current trust assets per public share, investment mix, and any redemptions or withdrawals since quarter-end.
- Cash available outside the trust and expected administrative, diligence, and transaction costs; the IPO note is due on demand and no longer available for further borrowing.
- Transaction financing, expected redemptions, the deferred underwriting fee, and potential dilution from founder-share conversion, rights, or any working-capital loans.
- Whether sponsor indemnification obligations are financially supportable and how any creditor claims could affect trust proceeds.